Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals.
Authors: Berlin S, Wallstabe S, Scheuch E, Oswald S, Hasan M, Wegner D, Grube M, Venner M, Ullrich A, Siegmund W
Journal: Equine veterinary journal
Summary
# Editorial Summary Rhodococcus equi pneumonia in foals remains a serious condition typically managed with rifampicin combined with macrolide antibiotics, yet established combinations like rifampicin–clarithromycin carry significant pharmacokinetic risks due to enzyme induction and inhibition that can compromise therapeutic efficacy. Berlin and colleagues investigated whether gamithromycin, a newer long-acting macrolide with minimal hepatic metabolism, might offer safer co-administration with rifampicin by examining drug interactions across single and multiple dosing protocols in healthy foals using plasma sampling and non-compartmental analysis. The researchers found that rifampicin induced gamithromycin metabolism—increasing clearance and reducing systemic exposure—though the magnitude of interaction was considerably less pronounced than documented with clarithromycin, and gamithromycin showed minimal influence on rifampicin pharmacokinetics. These results suggest the rifampicin–gamithromycin combination presents a more favourable interaction profile than traditional regimens, potentially allowing more predictable drug exposure and reducing the need for therapeutic drug monitoring; however, clinicians should recognise that induction does still occur and may warrant dosage adjustment or interval optimisation in severe infections requiring maximum bioavailability.
Read the full abstract on PubMed
Practical Takeaways
- •When treating foals with severe Rhodococcus equi lung abscesses, consider gamithromycin with rifampicin as an alternative to clarithromycin-rifampicin combinations to avoid problematic drug interactions
- •Gamithromycin's poor metabolism profile makes it a more compatible partner drug with enzyme-inducing agents like rifampicin compared to other macrolides
- •Monitor foals receiving combined rifampicin therapy carefully, as enzyme induction can significantly alter macrolide antibiotic pharmacokinetics and treatment efficacy
Key Findings
- •Gamithromycin is poorly metabolised compared to clarithromycin, suggesting lower potential for CYP3A4-mediated drug interactions
- •Rifampicin can inhibit and/or induce drug metabolising enzymes (CYP3A4) and transport proteins (P-glycoprotein), creating significant pharmacokinetic interactions with macrolide antibiotics
- •Gamithromycin combined with rifampicin may offer a suitable alternative to rifampicin-clarithromycin combination therapy due to reduced interaction potential